The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

New Drug Application Submitted for Gilead’s Sofosbuvir

Back to News Homepage

Next

Hep C Research Chimps May Be Switched Out for Mice

Hep C Studies on Faldaprevir Will Be Heard at EASL

Print this page

Studies with and without interferon on faldaprevir (Boehringer Ingelheim’s Hepatitis C drug), will be presented at the EASL annual liver meeting this month.

Boehringer Ingelheim’s STARTVerso 1 Phase 3 hepatitis C data to be presented at EASL Congress

Published on April 10, 2013

Boehringer Ingelheim today announced that data from its pivotal STARTVerso™ 1 Phase 3 hepatitis C clinical trial have been accepted for oral presentation as a late-breaker at the International Liver Congress™ 2013: 48th Annual Meeting of the European Association for the Study of the Liver (EASL), taking place from April 24-28 in Amsterdam, The Netherlands.

The STARTVerso™ 1 trial evaluated faldaprevir (BI 201335), an investigational oral protease inhibitor specifically designed to target and inhibit viral replication in the liver, in combination with pegylated interferon and ribavirin (PegIFN/RBV). The study was conducted in treatment-naïve patients with genotype-1 infection, the most common and one of the most challenging types of hepatitis C to cure.

Continue reading this entire article:http://www.news-medical.net/news/20130410/Boehringer-Ingelheims-STARTVerso-1-Phase-3-hepatitis-C-data-to-be-presented-at-EASL-Congress.aspx

No Comments - be the first!
Share
Share

Previous

New Drug Application Submitted for Gilead’s Sofosbuvir

Back to News Homepage

Next

Hep C Research Chimps May Be Switched Out for Mice

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.